INTRODUCTION
Diabetes mellitus (DM) and coronary heart disease (CHD) has a close relationship with each other. Diabetes mellitus is an independent risk factor for CHD development (WHO, 2014) . Patients with a history of diabetes are more likely to suffer from CHD compared to individuals without diabetes (Unnikrishnan et al., 2016) . Diabetes mellitus and CHD are a major cause of mortality and morbidity globally (Fuster et al., 2010) . CHD with DM patients has higher mortality rate due to uncontrolled diabetes which further causes several dysfunctions such as insulin resistance, atherosclerosis, and myocardial infarction. Indian and international registry data confirmed that 30-40 percent DM patients have CHD in India (Ali et al., 2010) . It is documented that more than 65 percent of cardiac deaths are due to diabetes mellitus in which 75-80 percent were especially due to CHD (Xavier et al., 2008; Moss et al., 1991) .
Coronary heart disease can be treated by pharmacotherapy, Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary Artery Bypass Grafting (CABG), lifestyle management and non-invasive therapy known as Enhanced External Counter Pulsation (EECP) (Antman et al., 2008) . Enhanced external counterpulsation is US-FDA approved non-invasive therapy for treatment of CHD patients, which are not suitable, unresponsive, and unwilling for PTCA and CABG procedures. Enhanced external counterpulsation therapy increases retrograde aortic blood flow during the diastolic phase of heart pumping. The mechanical device called EECP comprises sequential compression over legs, thighs, and buttocks to direct blood flow towards the heart when it is in the resting position. This treatment is recommended for 35 hours, one hour per day for 7 weeks (5 days in a week) (Arora et al., 1999; Kumar et al., 2017) .
Coronary heart disease and DM comorbidity deteriorate physical functional capacity and Health-Related Quality of Life (HR-QoL) of patients (Taghadosi et al., 2014) . Bozorgi et al. and Singh et al. studies demonstrate that EECP may significantly improve health-related quality of life and exercise tolerance in diabetic and nondiabetic coronary heart disease patients (Bozorgi et al., 2014; Singh et al., 2018) . The 12 minutes run or walk test was developed by Kenneth H. Cooper in 1968 to assess physical functioning capacity and to estimate VO 2 max (maximum oxygen uptake). VO 2 max is the maximum volume of oxygen consumption during an intense walk or exercise. The maximal aerobic or functional capacity is defined at the point at which oxygen consumption is high (Bandyopadhyay et al., 2015) . Canadian Cardiovascular Society (CCS) angina scale is widely used to assess angina severity in coronary heart disease patients. This is a valid and reliable tool to evaluate angina severity, ranging from class I to class IV in CHD patients (Kaul et al., 2009) . Medical Research Council (MRC) scale is widely used to assess breathlessness or dyspnea status in CHD patients. This scale comprises five segments that define the entire range of respiratory infirmity from none (Grade 1) to almost a complete incapacity (Grade 5) (Bestall et al., 1999) .
The quality of life assessment of an individual is the status of well-being and feeling about their health and body functioning. SF-36 and SAQ are standard tools, which are used to assess general and disease specific health-related quality of life of CHD patients (Brazier et al., 1992) . Thompson et al. study provides evidence for reliability and validity of SF-36 scale used to assess the quality of life in CHD patients (Thompson et al., 2003) . Seattle angina questionnaire (SAQ) is a disease-specific quality of life assessment tool which has been shown to be a valid, reproducible and reliable tool to evaluate the treatment or intervention effectiveness in CHD patients (Dempster et al., 2000) . The SAQ scale is widely used and its validity and reliability towards health status are demonstrated (Spertus et al., 1995) . Enhanced external counterpulsation treatment helps in glycemic control which ultimately improve the health-related quality of life of diabetic patients and studies done by Linnemeier et al. and Ramasamy et al. validates the effectiveness of EECP in diabetes patients Ramasamy et al., 2015) .
Our study was designed to assess the physical functioning profile and health-related quality of life of DM and CHD comorbidity patients and Non-DM CHD patients treated with EECP therapy.
MATERIALS AND METHODS
A pretest-posttest designed prospective study was done at Science and Art of Living (SAAOL) Heart Center, New Delhi among diabetic and nondiabetic CHD patients. A total of 212 subjects were enrolled in the study using consecutive sampling techniques from April 2016 to May 2017. The study subjects were divided into two groups. The first group was CHD patients with DM while the second group subjects were CHD patients without DM.
Inclusion criteria
Coronary heart disease patients with and without DM (patients having diabetes duration maximum 5 years) aged between 30 to 75 years, who did not willingly go for invasive treatments (Coronary Artery Bypass Grafting [CABG] and Percutaneous Trans Coronary Angioplasty [PTCA] ) and agreed to participate in the study with valid written informed consent were enrolled.
Exclusion criteria
Patients having cardiac arrhythmia, coagulation disorder, deep vein thrombosis, vaso-occlusive disease, abnormal aortic aneurysm, cardiac valvular disorder, pregnancy, high blood pressure (higher than 180/110 mmHg), foot wounds, dialysis history and unable to give valid written consent were excluded from the study.
Study procedure
The study was initiated with the screening of diabetic and nondiabetic CHD patients from the SAAOL Heart Center, New Delhi. A total of 300 subjects were screened. Out of 300 subjects, 88 were excluded from the study because they refused to participate, refused to give written consent and not willing to adhere 12 months study follow up. Finally, 212 study subjects were enrolled as they fulfilled all study eligibility criteria and agreed to 12 months of the study follow-up. After enrollment, the study subjects were allocated in CHD patient with DM (CHD + DM group) and CHD patients without DM (CHD group). After this, the demographic profile (age, gender, etc.) , clinical history and physiological (systolic blood pressure, diastolic blood pressure, heart rate) profile, was done at baseline of all study subjects. Physical functioning capacity, SpO 2 level, VO 2 max, CCS angina status, and MRC dyspnea score assessed at baseline and followed at 6 and 12 months of study. Health-related quality of life of the study subjects was also assessed at baseline and followed at 6 and 12 months through SF-36 and Seattle Angina Questionnaire (SAQ).
Measurements

Physiological profile assessment
Systolic and diastolic blood pressure were measured at baseline, 6 and 12 months. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were recorded by qualified personnel through Diamond Clock Model blood pressure monitor. Heart rate & SpO 2 of all study subjects were assessed through pulse oximeter (ChoiceMMed MD300C2D) at baseline, 6 months, and 12 months.
Physical functioning assessment
Physical functional capacity was assessed through Cooper 12-minute walk test and VO 2 max. In the Cooper 12-minute walk the study subjects were allowed to walk for 12 minutes on a flat track and a pedometer was used to measure the distance they covered within 12 minutes. VO 2 max was used to assess the aerobic capacity of study subjects. It was calculated with the standard formula:
VO 2 max (ml/kg/min) = (22.351 × distances covered in kilometers) − 11.288.
Angina status was assessed through the Canadian Cardiovascular Society (CCS) grading of angina pectoris. Breathlessness or dyspnea status was assessed by the Medical Research Council (MRC) scale.
Health-related quality of life (HRQoL) assessment
The HRQoL of study subjects was assessed by using SF-36 and SAQ. HRQoL of CHD patients with and without DM was assessed through face to face interview and subjects were responding as they experienced problems related to mobility, normal working at work, study, personal care, leisure activities, family, pain, and depression/anxiety. Answers of the patients were recorded. Short Form-36 (SF-36) a multi-item scale comprising 36 questions was used to assess the general health-related quality of life of CHD patients with and without DM in eight health domains, namely; physical functioning, physical health problems, emotional problems, energy status, emotional well-being, body pain and general health status. The score generated for each health variable was from 0 to 100, with 0 denoting the worst and 100 the best possible health outcomes. Seattle angina questionnaire was used to assess disease-specific quality of life and it measures 5 domains to assess EECP effectiveness in diabetic and nondiabetic CHD patients. SAQ domains were the physical constraint, angina stability, angina severity, treatment satisfaction, and perceived disease.
EECP treatment
The EECP, an electro-mechanical device, consists of three paired pneumatic cuffs applied to the lower leg, upper leg and buttocks. The cuffs of the device were inflated sequentially during diastole with maximum pressure 300 mmHg and returning blood from the legs to the central circulation and producing aortic diastolic augmentation. This increases both venous return and cardiac output in coronary heart disease patients. In the next step, cuffs are deflated at end-diastole with reducing peripheral resistance and providing left ventricular supply.
The ECP PSK machine having the model; P-ECP/TI was used for the treatment of diabetic and nondiabetic coronary heart disease patients. Each subject underwent one hour per day EECP treatment for 35 days for 7 weeks (5 days in a week) with 280 mmHg pressure. All study subjects were followed up for 12 months after completion of EECP therapy. Physical functional capacity through Cooper 12-minutes' walk test, SpO 2 status, VO 2 max, CCS angina severity and dyspnea score with health-related quality of life (SF-36, SAQ) were assessed at 6th and 12th months of study follow up (Bestall et al., 1999; Bandyopadhyay et al., 2015; Kaul et al., 2009) .
Ethical approval and consent
Ethical permission for this study was obtained from the Institutional Ethics Committee of SAAOL Heart Center (Ref. No-IEC/SHRF/PhD/P-02/01.05.2016), New Delhi. Written informed consent was also taken from all study subjects before initiation of the study.
Statistical analysis
A senior Biostatistician analyzed the collected data using statistical package for the social sciences (SPSS) software version 21. Demographic and socioeconomic profile of the study subjects were compared using independent t-test. Descriptive analysis of mean, SD, independent t-test and paired sample t-test with 95% confidence interval and p-value <0.05 was considered statistically significant.
RESULTS
Recruitment and response rates of the study subjects
The study was initiated with the screening of total 300 diabetic and nondiabetic coronary heart disease patients from the study site. Out of 300 patients, 88 patients were excluded from the study because 26 patients refused to participate, 33 patients refused to give written consent and 19 patients did not agree to 12 months follow up. Finally, 212 study subjects were enrolled as they fulfilled all study eligibility criteria and agreed to 12 months of study follow up. After enrollment, the study subjects were allocated to coronary heart disease patients with diabetes mellitus and coronary heart disease patients without diabetes mellitus. Total 163 patients had completed the whole study with 12 months follow up, 49 patients did not complete whole study and follow up, so they were excluded from the final data analysis because of missing and incomplete data. Out of 49 patients, 24 patients were excluded from the CHD + DM group (13 patients left the treatment and migrated to abroad and 11 patients did not complete 12 months follow up) and 25 from the CHD group (9 patients migrated to different places,16 patients did not complete 12 months follow up). Finally, the data of 163 patients were analyzed. Study outlines and response rates of the study subjects are summarized in the consort diagram ( Table 1) .
Baseline demographic details with the medical history of diabetic and nondiabetic CHD groups
A total of 163 diabetic and nondiabetic CHD patients completed the study (12 months follow up). Out of total 163 subjects; n = 82 subjects were in the diabetic CHD group (first group) and n = 81 subjects were in the nondiabetic CHD group (second group). The total mean age of both the group was 59.6 ± 9.5 (mean ± SD) years in which mean age of diabetic CHD subjects were 60.5 ± 9.5 (mean ± SD) and nondiabetic CHD subjects were 58.6 ± 9.6 (mean ± SD) years. The male subjects were 50.4% in diabetic CHD and 49.6% in nondiabetic CHD group. Females were much higher (53.3%) in nondiabetic CHD as compared to diabetic CHD group (46.7%). In this study, urban subjects were higher (56.4%) in the diabetic CHD group and rural subjects were higher (55.3%) in nondiabetic CHD group. A number of subjects have obesity (63.1%) in nondiabetic CHD group as compared to diabetic CHD group (36.9%). There were more hypertensive (51.6%) patients in the diabetic CHD group as compared to nondiabetic CHD group (48.4%).
The family history of heart disease (62.5%) was higher in the diabetic CHD group as compared to nondiabetic CHD group (37.5%), similarly, the family history diabetes (83.3%) was also higher in the diabetic CHD group as compared to nondiabetic CHD subjects (16.7%). The average diabetes duration in diabetic CHD group subjects was 4 years. Smoker patients were higher (51.9%) in nondiabetic CHD group as compared to diabetic CHD group (48.1%) and similarly, tobacco user was higher (83%) in nondiabetic CHD group as compared to diabetic CHD group (17%). Physical activity was higher (53.2%) in nondiabetic CHD group as compared to diabetic CHD group (46.8%). The non-vegetarian subjects were higher (53.1%) in nondiabetic CHD group as compared to the diabetic CHD group (46.9%). Medical history, such as myocardial infarction was higher in diabetes CHD group (54.9%), similarly, the rate of PCI (62.9%) and CABG (58.7%) was also higher in diabetic CHD subjects. The history of single vessel CHD was similar in both the groups, but double vessel CHD patients were higher (62.8%) in nondiabetic CHD subjects while triple vessel CHD was higher (60%) in diabetic CHD subjects as compared to nondiabetic CHD subjects (40%). The detail of the demographic profile and medical history of diabetic and nondiabetic CHD groups is described in Table 2 . Effect of EECP on physiological parameters and physical capacity in diabetic and nondiabetic CHD patients The physiological parameters consist systolic blood pressure, diastolic blood pressure, heart rate and SpO 2 did not show any significant change between the groups from baseline to 12 months using independent t-test. A significant change has been observed in systolic blood pressure, diastolic blood pressure, heart rate and SpO 2 level from baseline to 6 months in diabetic CHD patients and similar outcomes sustained till 12 months in systolic blood pressure and SpO 2 level in both the groups. The detailed information has been given in Table 3 .
A significant change was observed in dyspnea score at baseline in male using MRC scale but at 6 months and 12 months follow up no statistical change was observed. There was no significant change between the group in Cooper 12 minute walk test (walking distance), VO 2 max and CCS angina classifications were observed in diabetic and nondiabetic CHD group patients. The details of findings have been given in Table 4 .
Effect of EECP on health-related quality of life (HRQoL) in diabetic and nondiabetic CHD patients
A significant improvement was observed in all SF-36 scale domains from baseline to 12 months with significant pvalues <0.001. The significant changes were also observed in, energy level, social functioning, and general health after 6 months of EECP treatment between the groups but these differences did not maintain until 12 months. The difference between the groups was assessed using independent t-test. The details of SF-36 study outcomes have been given in Table 5 .
All domains of SAQ scale yielded significant improvement within both (diabetic & nondiabetic CHD) groups from baseline to 12 months as assessed through paired sample t-test. Significant improvement in treatment satisfaction and disease perception after the 12 months of EECP treatment has been observed in both diabetic and nondiabetic CHD groups. There was no significant difference observed between both the groups from baseline to 6th months and 12th months of EECP treatment, assessed through the independent t-test. The details of SAQ results have been given in Table 6 .
DISCUSSION
The aim of the present study was to assess the effect of EECP therapy on the physical functional status and health-related quality of life in diabetic and nondiabetic CHD patients. Our study demonstrates significant improvement in blood pressure, heart rate, and SpO 2 level after EECP treatment in both groups. Beck et al. and Casey et al. study also indicated that EECP may be useful as an adjuvant therapy for improving functional capacity in coronary heart disease patients through reductions in blood pressure and improvement in myocardial oxygen demand for better physical functioning (Beck et al., 2015; Casey et al., 2011) . Diabetic and nondiabetic CHD patients demonstrate significant improvement in walking status, exercise tolerance with increment in VO 2 max levels after EECP therapy. Similarly, studies done by Feldman et al. and Urano et al. have supported the findings of the present study (Feldman et al., 2006; Urano et al., 2001 ). In the present study, a significant improvement was observed in the physical functional capacity in coronary heart disease patients after EECP therapy and similar findings have been reported by Rampengan et al. and May et al. in their study (Rampengan et al., 2015; May et al., 2015) . Before EECP treatment our study subjects were mostly poor in physical functional capacity but after EECP treatment they significantly improved. A significant effect of EECP treatment on CCS angina class and dyspnea improvement has been observed in this study in diabetic and nondiabetic coronary heart disease patients. Studies done by Chung-Kuan et al. & Ziaeirad et al. (Chung-Kuan et al., 2014; Ziaeirad et al., 2012) have shown similar findings. The results of our study are in agreement with Petterson et al. and Loh et al. studies which have shown significant results on the effectiveness of EECP in patients with angina (Pettersson et al., 2006; Loh et al., 2006) . Soran et al. study also reported similar findings in the present study .
A significant improvement has been observed in healthrelated quality of life using SF-36 and SAQ scale and Arora et al. have reported similar findings (Arora, 1999) . A significant improvement has been observed in all SAQ domains using the paired t-test to assess differences within groups from baseline to 12 months showed significant changes in both groups after EECP treatment. These results demonstrate similar outcomes in diabetic and nondiabetic CHD patients treated with EECP therapy. Our study shows improvement in the quality of life in diabetic and nondiabetic CHD patients and supported by the research done by Linnermeir et al. and Michaels et al. (Linnemeier et al., 2003; Michaels et al., 2004) .
A significant improvement was observed in the quality of life with similar clinical outcomes of Ziaeirad et al. in diabetic and nondiabetic coronary heart disease patients. The author reported significant improvements in quality of life of coronary heart patients in all domains of SF-36, a standard questionnaire of quality of life assessment (Ziaeirad et al., 2012) . SF-36 tool used by Arora et al. showed significant results on physical activity, general health with reduction of bodily pain and similarly Manchanda et al. indicated good results of EECP in respect of the improvement in the quality of life for heart patients (Manchanda et al., 2007) . In the present study, overall, general health status had improved, and it is supported with the data of earlier studies to demonstrate the clinical significance of EECP health-related quality of life of coronary heart disease patients (Wu et al., 2012) . Our study showed similar results in diabetic and nondiabetic CHD patients and no major significant difference has been observed in diabetic and nondiabetic CHD group using independent t-test in physical functional capacity and healthrelated quality of life. Eslamian et al. concluded that EECP therapy can improve the angina pectoris stability and severity of disease perception (Eslamian et al., 2013) . Similarly, our study demonstrates that both diabetic and nondiabetic coronary heart disease patients get good results in almost all domains of SAQ quality of life assessment scale.
Enhanced external counterpulsation is an effective treatment method for diabetes management and diabetes complication including CHD. It helps in lowering blood glucose level of alerting transport of insulin into skeletal muscle and thereby help in the glycemic control and ultimately improve the healthrelated quality of life of diabetic CHD patients. Linnemeier et al., Martin et al., and Ramasamy et al. studies validate the effectiveness of EECP towards glycemic control in DM patients Martin et al., 2012; Ramasamy et al., 2015) .
Our study reveals that EECP significantly improves the health-related quality of life and remained high for the following one year in diabetic and nondiabetic CHD patients. Jorgensen et al. study demonstrated that the effect of EECP on quality of life sustained for three years in CHD patients (Jorgensen et al., 2013) . Hence, there is further need to conduct a multicentric randomized controlled trial to assess long-term effects of enhanced external counterpulsation on health-related quality of life in diabetic CHD patients.
CONCLUSIONS
The results of the present study conclude that enhanced external counterpulsation therapy may improve walking capacity, maximal oxygen uptake and peripheral capillary oxygen saturation of diabetic and nondiabetic CHD patients. This non-invasive procedure also significantly improves the clinical symptoms (angina & dyspnea) of CHD patients with and without DM. Enhanced external counterpulsation therapy may also improve overall health-related quality of life of diabetic and nondiabetic CHD patients, including angina severity, angina stability, and general health. In the summary, enhanced external counterpulsation therapy is safe, well tolerated and proved to be an effective, non-invasive therapy to treat diabetic and nondiabetic CHD patients. It may improve the physical profile and quality of life in both diabetic and nondiabetic CHD patients equally. There is further need of multicentric randomized controlled trials to assess long-term effects of enhanced external counterpulsation on health-related quality of life in a larger population of CHD with DM patients.
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